Medidur + Lucentis trial underway

Article

A pilot study evaluating the safety and efficacy of Medidur FA (fluocinolone acetonide; Alimera) with Lucentis (ranibizumab; Novartis) against exudative age-related macular degeneration (wet AMD) has begun patient enrolment.

A pilot study evaluating the safety and efficacy of Medidur FA (fluocinolone acetonide; Alimera) with Lucentis (ranibizumab; Novartis) against exudative age-related macular degeneration (wet AMD) has begun patient enrolment.

Medidur FA is an intravitreal implant, currently in Phase III testing for diabetic macular oedema (DME), which delivers fluocinolone acetonide to the retina for up to three years.

The pilot study will evaluate the impact of Medidur FA on visual acuity and retinal thickness in patients who have been treated with Lucentis for a minimum of six months. Two doses of Medidur FA will be compared: 0.2 and 0.5 µg/day. The number of further Lucentis injections required after Medidur FA treatment begins will also be assessed.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.